StockMatusow

About the Author StockMatusow

Scott is an independent investor/writer/trader and team leader of StockMatusow.com. He has have about fifteen years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account. Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things 'outside the box.' Scott uses his ability to read situations and emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements. Using these allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. Scott has his own online talk show which can be heard at www.scottmatusow.com/radio . During market hours, we engage in talk about Stocks and Politics. After hours, Scott engages in a variety of talk issues from Poker, Sports, Politics, Current Events and whatever the chat room people wish to talk about. Other places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Kyle Dennis; writer, analyst, trader, website design, and team member of Stockmatusow.com. Kyle has a Biology degree from the University of California Los Angeles (UCLA) and specializes in trading the biotechnology sector. Kyle has extensive experience in researching, writing, and editing articles that have been published in scientific journals. He uses these experiences to write and comment about the potential of various biotechnology companies. Kyle specializes in evaluating trial success, drug potential, and market valuations. As an investor/trader, Kyle likes to focus on chart analysis and investor/trader sentiment to identify good entry and exit points. Kyle can also be followed at www.twitter.com/kylewdennis @kylewdennis Michael Kovar; writer, editor, investor, trader and team member of stockmatusow.com Michael has spent over ten years in financial roles with companies large and small. Recently, he spent time in a consulting role with Thomson Reuters legal headquarters in Eagan, MN. He currently works in an analyst position with a healthcare organization. Since 2011, Michael has worked with Scott Matusow to help research and edit articles for Stockmatusow.com.

3 Small Cap Biotechs with Upcoming Catalysts

Written by Danny Cohen of stockmatusow.com BiolineRx (BLRX) is slated to report on complete data at the European Society for Medical Oncology (ESMO) …

3 Biotechs with Upcoming Data to Watch

Written by Dan Cohen and Scott Matusow Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in …

Recent Sell-Off in Jounce therapeutics’ (JNCE) Stock Is Unwarranted

Written by Dan Cohen In the wake of recently revealed abstracts from the 2018 ASCO meeting, Jounce therapeutics (NASDAQ:JNCE) stock price recently took …

4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE)

Written by Danny Cohen and Scott Matusow The biotech “run-up” trade has always attracted a wide-array of traders looking to take advantage of …

There’s More Than Meets The Eye With Calithera Biosciences

Written by Danny Cohen And Scott Matusow This past weekend at The Society for Immunotherapy of Cancer (SITC) Calithera Biosciences Inc (NASDAQ:CALA) presented a …

4 Biotechs to Keep an Eye on for the Annual Ash Meeting

Written by Dan Cohen and Scott Matusow from Stockmatusow.com.

Myokardia Inc: A New Approach in Cardiomyopathy Treatment

Written by Dan Cohen and Scott Matusow Currently, we are in the midst of a dramatic shift in the field of biotechnology and …

GlycoMimetics Inc (GLYC): Undervalued Biotech with Significant Potential

 Written by Dan Cohen and Scott Matusow At Stockmatusow, our primary focus is finding clinical stage biotech companies that have the potential to …

Calithera Biosciences Inc: A Growing Player in the Immune System (Part II)

Written by Dan Cohen and Scott Matusow After consistent disappointments in the development of agents to treat metastatic triple-negative breast cancer (TNBC), novel …

Calithera Biosciences Inc: A Growing Player in the Immune System (Part I)

Written by Dan Cohen and Scott Matusow These days, it seems as if every major pharmaceutical company is working on their own PD-1 targeted therapeutic regimen …